Table 1

Study characteristics and lipid profiles for HCQ users (group 1) and non-users (group 2)

StudyGroupNOngoing treatments (%)Results (mg/dL)
(mean (SD) or median (IQR))
MTXNon-HCQ csDMARDsTNFiCSTCLDLHDLTG
Kerr et al 25 Group 1150NR952141186.1 (31.8)108.6 (3)53.0 (10.9)124.1 (39.3)
Group 2638NR712540204 (41.8)119.7 (48.7)46.7 (15.7)153.5 (59.9)
Penn et al 26 Group 131NR262347201 (33)112 (30)63.7 (15.6)116 (94, 142)
Group 2146NR523340210 (37)123 (35)60.5 (14.4)121 (84, 156)
Restrepo et al 27 Group 1109NRNRNRNR181.2 (35.6)97.5 (29.7)60.4 (18.4)115.1 (56.9)
Group 2836NRNRNRNR185.6 (40.4)106.5 (33.6)52.7 (16.3)132.2 (81.2)
Solomon et al 32 Group 1237030579179.7 (44.3)101.7 (36.7)59.4 (18.2)92.4 (41.7)
Group 2237030579189.4 (37.9)109.9 (33.1)60.3 (17.8)91.6 (44.9)
Rho et al 28 Group 142NRNRNRNRNR103.7 (27.8)50.4 (14.1)105.5 (50.5)
Group 2127NRNRNRNRNR115.6 (34.7)45.3 (13.7)157.7 (202.6)
  • CS, corticosteroid; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MTX, methotrexate; NR, not reported; TC, total cholesterol; TG, triglycerides; TNFi, TNF inhibitors.